Oncocyte Total Revenue

The latest total revenue for OCX is $1.7M as of June 2026. That compares with $4.3M in the prior-year period — down 60.8% year over year. That is below the Technology sector average of $37T. Investors often review this figure alongside Oncocyte's historical trend and sector peers before judging valuation or financial health.

Over the past year, OCX's total revenue moved from $4.3M to $1.7M — a 60.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Oncocyte's operating scale or balance-sheet position.

Against Technology companies, OCX currently prints $1.7M for total revenue, while the sector average sits near $37T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Oncocyte's growth, margins, and balance sheet.

A total revenue figure of $1.7M for OCX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Technology average is about $37T. Explore the charts below for those layers of context.

After noting OCX's total revenue ($1.7M), review year-over-year change from $4.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.